CMC – Page 8 – Pharma.Tips

Regulatory Strategy for Pilot to Commercial Scale-Up

Addressing the Regulatory Challenges in Scale-Up from Pilot to Commercial Manufacturing Scaling up production from pilot to commercial stages presents a range of regulatory challenges that can impact the entire…

Regulatory Strategy for Pilot to Commercial Scale-Up

Understanding the Regulatory Filing Consequences from Pilot to Commercial Scale-Up In the journey from pilot to commercial scale-up in pharmaceutical manufacturing, organizations often encounter significant regulatory challenges that can hinder…

How Scale-Up Changes Affect CMC Regulatory Filings

Understanding the Impact of Scale-Up on CMC Regulatory Filings Pharmaceutical companies frequently face challenges when scaling up manufacturing processes. The transition from small-scale production to commercial manufacturing can impact Chemistry,…

Regulatory Filing Impact of Scale-Up in Pharmaceutical Manufacturing

Addressing the Regulatory Challenges of Scale-Up in Pharmaceutical Manufacturing As pharmaceutical companies strive to meet increasing market demands, the scale-up of manufacturing processes often presents significant regulatory hurdles. The challenge…

Regulatory Filing Impact of Scale-Up in Pharmaceutical Manufacturing

Understanding the Impact of Scale-Up on Regulatory Filings in Pharmaceutical Manufacturing In pharmaceutical manufacturing, the scale-up process poses significant challenges that can directly affect regulatory filings. As companies expand production…

Process performance not reproduced during contract manufacturing onboarding – inspection-ready documentation

Addressing Issues in Contract Manufacturing Onboarding for Process Performance Reproduction In the realm of pharmaceutical production, engaging contract manufacturing organizations (CMOs) poses unique challenges, particularly when process performance is not…

CPPs not well defined during lifecycle optimization – preventing downstream validation failure

Avoiding Downstream Validation Failures: Defining CPPs During Lifecycle Optimization In pharmaceutical manufacturing, the definition and management of Critical Process Parameters (CPPs) play a crucial role throughout the product lifecycle. Undefined…

Process performance not reproduced during commercial scale-up – risk-based scale-up strategy

Addressing Inconsistent Process Performance During Scale-Up in Pharmaceuticals In the landscape of pharmaceutical manufacturing, ensuring consistent process performance during scale-up is critical to product quality and regulatory compliance. When a…

Equipment differences overlooked during site transfer – inspection-ready documentation

Understanding Equipment Discrepancies During Site Transfers: A Practical Guide for Validation and Compliance Equipment discrepancies during site transfers can significantly impact drug manufacturing processes, leading to quality issues, compliance failures,…

Site capability mismatch during contract manufacturing onboarding – tech transfer governance model

Addressing Site Capability Mismatch in Contract Manufacturing Onboarding: A Governance Model In the context of pharmaceutical contract manufacturing onboarding, site capability mismatches can disrupt formulation and process development, posing risks…

Tech transfer package incomplete during contract manufacturing onboarding – preventing repeat tech transfer issues

Preventing Issues with Incomplete Tech Transfer Packages During Contract Manufacturing Onboarding In today’s dynamic pharmaceutical landscape, the adequacy of tech transfer packages significantly impacts the success of contract manufacturing onboarding…

Equipment differences overlooked during site transfer – CAPA for transfer failures

Addressing Overlooked Equipment Differences in Site Transfers – A Comprehensive CAPA Playbook In the complex world of pharmaceutical manufacturing, the nuances of equipment differences during site transfers can lead to…